Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study I)
This study has been completed.
Study NCT00772538
Information provided by Boehringer Ingelheim Pharmaceuticals
First Received on October 13, 2008.
Last Updated on October 15, 2012
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
